Christopher Jennison

Bath, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.

Journal: Nature reviews. Drug discovery

Published: June 08, 2026

Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.

Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.

Journal: Genome medicine

Published: October 10, 2025

Clinical trials with interim analyses: standardizing terminology to increase clarity.

Clinical trials with interim analyses: standardizing terminology to increase clarity.

Journal: Trials

Published: November 30, 2024

Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial.

Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial.

Journal: Statistics in medicine

Published: July 01, 2024

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists.

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists.

Journal: medRxiv : the preprint server for health sciences

Published: April 24, 2023

Discussion on "Adaptive enrichment designs with a continuous biomarker" by N. Stallard.

Discussion on "Adaptive enrichment designs with a continuous biomarker" by N. Stallard.

Journal: Biometrics

Published: November 11, 2021

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.

Journal: BMJ open

Published: December 29, 2020

Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study.

Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study.

Journal: Diabetes care

Published: June 24, 2020

Adaptive enrichment trials: What are the benefits?

Adaptive enrichment trials: What are the benefits?

Journal: Statistics in medicine

Published: March 05, 2020

Authors' reply.

Authors' reply.

Journal: Statistics in medicine

Published: October 04, 2019

Improved two-stage group sequential procedures for testing a secondary endpoint after the primary endpoint achieves significance.

Improved two-stage group sequential procedures for testing a secondary endpoint after the primary endpoint achieves significance.

Journal: Biometrical journal. Biometrische Zeitschrift

Published: November 08, 2017

Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study.

Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: July 04, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026